4 citations,
January 2020 in “Skin appendage disorders” A woman with an unusual pattern of hair loss was confirmed to have Frontal Fibrosing Alopecia and treated with specific medications.
35 citations,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
1 citations,
November 2014 The document explains hair and nail biology, common hair loss conditions and treatments, oral and genital skin diseases, and the risks and treatments associated with squamous cell carcinoma.
54 citations,
April 2010 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” Impaired androgen production in 46,XY DSDs causes ambiguous genitalia and requires long-term care.
12 citations,
October 2012 in “Dermatologic Clinics” Low-Level Laser Therapy and other light treatments for hair growth lack strong evidence and need more research.
22 citations,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
2 citations,
April 2017 in “Actas Dermo-Sifiliográficas” Best treatment for Frontal Fibrosing Alopecia is 5-alpha-reductase inhibitors and intralesional corticosteroids.
1 citations,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
1 citations,
October 2022 in “International Journal of Environmental Research and Public Health” People with Type 2 Diabetes are more likely to have a mite infestation called Demodex folliculorum.
10 citations,
September 2022 in “Journal of Biophotonics” Blue light therapy is safe for skin and may protect against UV radiation.
December 2015 in “Vascular Pharmacology” Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.
35 citations,
January 2014 in “Journal of Tissue Engineering” Cell-based therapies using dermal papilla cells and adipocyte lineage cells show potential for hair regeneration.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
16 citations,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
1 citations,
May 2017 in “InTech eBooks” The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
65 citations,
November 2016 in “Journal of The American Academy of Dermatology” The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
39 citations,
January 2012 in “Acta dermato-venereologica” Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.
290 citations,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
74 citations,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
22 citations,
April 2022 in “Stem cell research & therapy” Hair follicle-derived extracellular vesicles may help heal chronic wounds as effectively as those from adipose tissue.
20 citations,
June 2010 in “Genes and Immunity” Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.
1 citations,
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Fetal skin has unique immune cells different from adult skin.
5 citations,
June 2012 in “Journal of Investigative Dermatology” A new mouse model for vitiligo helps study immune responses and potential treatments.
6 citations,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.